USANA Health Sciences (USNA) Issues Earnings Results

USANA Health Sciences (NYSE:USNA) released its earnings results on Tuesday. The company reported $1.32 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.33 by ($0.01), Bloomberg Earnings reports. The firm had revenue of $299.02 million during the quarter, compared to analysts’ expectations of $305.79 million. USANA Health Sciences had a net margin of 7.57% and a return on equity of 29.67%. USANA Health Sciences’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the company posted $1.11 earnings per share. USANA Health Sciences updated its FY19 guidance to $5.25-5.55 EPS.

Shares of USNA stock opened at $117.19 on Wednesday. The stock has a market cap of $2.78 billion, a PE ratio of 28.86 and a beta of 0.53. USANA Health Sciences has a 1-year low of $69.55 and a 1-year high of $137.95.

Several brokerages have recently weighed in on USNA. ValuEngine lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Thursday, November 8th. Sidoti upgraded shares of USANA Health Sciences from a “neutral” rating to a “buy” rating in a report on Thursday, October 25th. Finally, Pivotal Research upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating and set a $135.00 price objective on the stock in a report on Wednesday, October 24th.

In related news, Director Feng Peng sold 282 shares of the firm’s stock in a transaction that occurred on Tuesday, November 27th. The shares were sold at an average price of $120.15, for a total value of $33,882.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Myron W. Wentz purchased 6,697 shares of the business’s stock in a transaction that occurred on Friday, December 7th. The stock was acquired at an average price of $70.46 per share, for a total transaction of $471,870.62. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 19,117 shares of company stock worth $1,349,965 and have sold 178,660 shares worth $20,014,735. Corporate insiders own 48.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in USANA Health Sciences by 10.7% in the third quarter. Vanguard Group Inc. now owns 1,245,807 shares of the company’s stock valued at $150,182,000 after buying an additional 120,709 shares during the period. Vanguard Group Inc raised its holdings in USANA Health Sciences by 10.7% in the third quarter. Vanguard Group Inc now owns 1,245,807 shares of the company’s stock valued at $150,182,000 after buying an additional 120,709 shares during the period. BlackRock Inc. raised its holdings in USANA Health Sciences by 11.8% in the third quarter. BlackRock Inc. now owns 1,076,327 shares of the company’s stock valued at $129,750,000 after buying an additional 113,961 shares during the period. Prudential Financial Inc. raised its holdings in USANA Health Sciences by 11.1% in the third quarter. Prudential Financial Inc. now owns 287,082 shares of the company’s stock valued at $34,608,000 after buying an additional 28,659 shares during the period. Finally, Deutsche Bank AG raised its holdings in USANA Health Sciences by 21.8% in the third quarter. Deutsche Bank AG now owns 246,002 shares of the company’s stock valued at $29,653,000 after buying an additional 44,038 shares during the period. Hedge funds and other institutional investors own 54.39% of the company’s stock.

USANA Health Sciences declared that its Board of Directors has authorized a stock buyback program on Tuesday, October 23rd that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 5.9% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: “USANA Health Sciences (USNA) Issues Earnings Results” was first reported by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://theenterpriseleader.com/2019/02/06/usana-health-sciences-usna-issues-earnings-results.html.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

See Also: How to interpret the current ratio

Earnings History for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply